A Placebo-Controlled Trial of Lisdexamfetamine in the Treatment of Comorbid Sluggish Cognitive Tempo and Adult ADHD
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Objective: To examine the efficacy of lisdexamfetamine (LDX) versus placebo on behavioral attributes of sluggish cognitive tempo (SCT) in adults with attention-deficit/hyperactivity disorder (ADHD) and SCT. Methods: In a randomized crossover trial conducted January 2016-April 2018, 38 adults with DSM-5 ADHD (via the Adult ADHD Clinical Diagnostic Scale v1.2) and SCT were recruited at 2 academic medical centers and assessed for symptoms of ADHD, SCT, executive function deficits, and functional impairment at baseline and weekly during treatment. Participants received 4 weeks of treatment with either LDX (30-70 mg/d; mean = 59.1 ± 14.8 mg/d) or matching placebo (mean = 66.6 ± 9.1 mg/d) with a 2-week washout before switching to the other arm. The ADHD Rating Scale and Barkley Adult ADHD Rating Scale-IV SCT subscale were coprimary outcome measures. Results: There were moderately large treatment effects of LDX vs placebo on SCT ratings in both treatment periods (block 1 effect size = 0.68; block 2 effect size = 0.61), which reached significance only in block 1 owing to carryover effects of the first treatment epoch into the second. Significant effects were also seen for LDX over placebo in ADHD, executive function deficit, and functional impairment ratings, without order effects; no site differences were seen except on the Global Executive Complex score of the Behavior Rating Inventory of Executive Function-Adult Version. No moderating effects of sex, age, race, and ethnicity were…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A RCT of children with ADHD suggested increased SCT Sluggish/Sleepy, but not Daydreaming, scores were linked to methylphenidate non-response and diminished dose-response for inattention symptoms.158”
From Report of a Work Group on Sluggish Cognitive Tempo: Key Research Directions and a Consensus Change in Terminology to Cognitive Disengagement Syndrome (2023) · cites this paper as [158]
In the citing paper
“At present, the limited existing literature suggests that psychostimulants such as methylphenidate and lisdexamfetamine, as well as atomoxetine, may improve CDS symptoms, although replication and research on related medications is needed.”
In the citing paper
“A randomized controlled trial of 38 adults (mean age = 34.6 years) with ADHD and co-occurring elevated CDS symptoms found that, compared with placebo, lisdexamfetamine improved CDS symptoms with moderately large effect sizes (Cohen’s d = 0.61–0.68) [52].”
In the citing paper
“Although initial findings suggest that methylphenidate, lisdexamfetamine, and atomoxetine may improve CDS symptoms, it is important to underscore that the current evidence is based on very few studies (i.e., one study sample for each medication has been examined) with both small and limited samples.”
In the citing paper
“Of note, treatment-related change scores for ADHD and CDS ratings were only modestly correlated (shared variance of 24%), suggesting partial distinctiveness of these two constructs and their lisdexamfetamine response [52].”
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Cited by
Becker, S. P., Willcutt, E. G., Leopold, D. R., Fredrick, J. W., Smith, Z. R., Jacobson, L. A., Burns, G. L., Mayes, S. D., Waschbusch, D. A., Froehlich, T. E., et al. (2023) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2022.07.821 · Cited by 175
Cortese, S., Bellgrove, M. A., Brikell, I., Franke, B., Goodman, D. W., Hartman, C. A., Larsson, H., LEVIN, F. R., Ostinelli, E. G., Parlatini, V., et al. (2025) · World Psychiatry · doi:10.1002/wps.21374 · Cited by 114
Self-citationPagán, A. F., Huizar, Y. P., Short, T. R., Gotcher, Z., & Schmidt, A. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01280-4 · Cited by 34
The Therapeutic Potential of Amphetamine-like Psychostimulants
Pires, B., Rosendo, L. M., Brinca, A. T., Simão, A. Y., Barroso, M., Rosado, T., & Gallardo, E. (2023) · Life · doi:10.3390/life13112180 · Cited by 26
Wiggs, K. K., Froehlich, T. E., & Becker, S. P. (2023) · CNS Drugs · doi:10.1007/s40263-023-00999-5 · Cited by 16
“Of note, treatment-related change scores for ADHD and CDS ratings were only modestly correlated (shared variance of 24%), suggesting partial distinctiveness of these two constructs and their lisdexamfetamine response [52].”
Background
Metadata
- Authors
- Adler, L. A., Leon, T. L., Sardoff, T. M., Krone, B., Faraone, S. V., Silverstein, M. J., & Newcorn, J. H.
- Affiliations
- NYU Langone Health (US)
- New York University (US)
- Icahn School of Medicine at Mount Sinai (US)
- SUNY Upstate Medical University (US)
- Corresponding author
- Adler, Lenard A.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2021-06-29
- Volume
- 82
- Issue
- 4
- ISSN
- 0160-6689 (ISSN-L)
- 1555-2101
- OpenAlex
- W3175616451
- Cited by
- 24
- References
- 0
- Citations by year
- 2026: 9 · 2025: 5 · 2024: 2 · 2023: 5 · 2022: 2 · 2021: 1
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- lisdexamfetamine, sluggish cognitive tempo, adult ADHD, comorbidities, stimulant medication, executive dysfunction, functional disability, ADHD Rating Scale, residual effects
- MeSH terms
- Lisdexamfetamine Dimesylate, Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Cognition Disorders, Double-Blind Method, Female, Humans, Male, Psychiatric Status Rating Scales, Cross-Over Studies, Executive Function
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Placebo-Controlled Trial of Lisdexamfetamine in the Treatment of Comorbid Sluggish Cognitive Tempo and Adult ADHD. https://app.cochat.ai/papers/10.4088/jcp.20m13687
- The paper
- Adler, L. A., Leon, T. L., Sardoff, T. M., Krone, B., Faraone, S. V., Silverstein, M. J., & Newcorn, J. H. (2021). A Placebo-Controlled Trial of Lisdexamfetamine in the Treatment of Comorbid Sluggish Cognitive Tempo and Adult ADHD. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.20m13687
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.